Copy Link Print Information

Pembrolizumab (anti-PD-1)

(Synonyms: MK-3475 (anti-PD-1); Lambrolizumab (anti-PD-1))
35 Cited Publications
Customer Review

Based on 35 publication(s) in Google Scholar

Pembrolizumab (anti-PD-1) is a humanized IgG4 antibody and PD-1 inhibitor. Pembrolizumab produces PD-1 blockade, preventing PD-L1 and PD-L2 from connecting to PD-1. This avoids the uncontrolled regulation of T cells on cells that normally express PD-1.

For research use only. We do not sell to patients.

  • Purity: 99.9%
  • Molecular Weight:146.341 kDa
  • Storage:

    Please store the product under the recommended conditions in the Certificate of Analysis.

  • Experimental Validation Results for Pembrolizumab (anti-PD-1)
  • Experimental Validation Results for Pembrolizumab (anti-PD-1)
  • Experimental Validation Results for Pembrolizumab (anti-PD-1)
  • Experimental Validation Results for Pembrolizumab (anti-PD-1)
  • Experimental Validation Results for Pembrolizumab (anti-PD-1)
  • Experimental Validation Results for Pembrolizumab (anti-PD-1)
  • Experimental Validation Results for Pembrolizumab (anti-PD-1)
  • Experimental Validation Results for Pembrolizumab (anti-PD-1)
  • Experimental Validation Results for Pembrolizumab (anti-PD-1)
  • Experimental Validation Results for Pembrolizumab (anti-PD-1)
  • Pembrolizumab (anti-PD-1) Chemical Structure
    Pembrolizumab (anti-PD-1) Chemical Structure
Size
Price
Stock
Quantity
Amount: USD 0.00
Please select quantity
or
or

* Please select Quantity before adding items.

To place orders, for customer services and technical support, please contact: MedChemExpress USA

Tel: 609-228-6898 E-mail: [email protected] [email protected]

Data Download
Other Forms of Pembrolizumab (anti-PD-1):

To place orders, for customer services and technical support, please contact:

609-228-6898
[email protected] [email protected]
Find Your Local Distributor Your local distributor: Hycultec GmbHHycultec
  • Biological Activity
  • Chemical Information
  • Purity & Documentation
  • References
  • Help & FAQs
Top Publications Citing

Use of MCE Products

Publications Citing Use of MedChemExpress (MCE) Pembrolizumab (anti-PD-1)

More
Customer Validation & Images
In Vivo Efficacy StudyFlow CytometryIFOthersCell Migration/Invasion Assay
  • In Vivo Efficacy Study
  • IF
  • Cell Migration/Invasion Assay
  • Flow Cytometry
  • Others
  • In Vivo Efficacy Study
  • In Vivo Efficacy Study
  • IF
Keywords
MOQ
Minimum order quantity
100 mg

Get Quote In-stock

Other size
Get Quote
Please select quantity
Amount: USD 0.00
Sign in to MedChemExpress Sign In
Register
Sign in to MedChemExpress
Register New Account

At least 6 characters

Personalize your experience, you are currently not signed in. For a better experience, please create an online profile, you can:

Obtain points redemption prizes
Check out faster
Add multiple shipping locations
View orders
Assay Types
  • 1/16

    Human IgG4 kappa

  • 1/16

    Flow cytometry analysis of PD-1 overexpression HEK293 cells labelling PD-1 with Pembrolizumab at 67nM (Red). Goat anti human IgG Fc(Alexa Fluor488) was used as the secondary antibody at 1/400 dilution. Isotype control - human IgG (Blue). Unlabeled control - Unlabelled cells (Gray).

  • 1/16

    Pembrolizumab (anti-PD-1) purchased from MedChemExpress. Usage Cited in: Cancer Commun (Lond). 2025 Aug;45(8):1010-1037. [Abstract]

    Customer Validation
     Plots of tumor growth and tumor weight for each group (5 mice/group). The results showed that in mice, the combination of Pembrolizumab and Evolocumab significantly enhanced anti-tumor efficacy compared to Pembrolizumab alone (100 µg/mouse; i.p., every 7 days).

  • 1/16

    Pembrolizumab (anti-PD-1) purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2025 Jan 21;16(1):34. [Abstract]

    Customer Validation
     Pembrolizumab (pembro) (5-10 µg/mL, 24 h). AMM16 cells were transfected with control siRNA (siRNA ctrl; left panels) or AR siRNA (siRNA AR; right panels) and treated with the indicated ICIs at 35 μg/ml. The red fluorescence from the propidium iodide (PI) and the green fluorescence from the acridin orange (AO) staining indicate dead and total cells, respectively.

  • 1/16

    Pembrolizumab (anti-PD-1) purchased from MedChemExpress. Usage Cited in: Mol Med. 2025 Aug 16;31(1):278. [Abstract]

    Customer Validation
     Scratch assay comparing the migration ability of MDA-MB-231/PEM and MDA-MB-231 cells treated with 10 µg/mL Pembrolizumab (PEM).

  • 1/16

    Pembrolizumab (anti-PD-1) purchased from MedChemExpress. Usage Cited in: J Immunother Cancer. 2024 Aug 6;12(8):e009024. [Abstract]

    Customer Validation
     The PD-1 expression of macrophages isolated from the subcutaneous tumor microenvironment of mice was detected by flow cytometry (n=5). The results showed that Pembrolizumab (anti-PD-1 Ab) (20 µg/mL, 24 h) reduced PD-1 expression.

  • 1/16

    Pembrolizumab (anti-PD-1) purchased from MedChemExpress. Usage Cited in: Nat Commun. 2022 Jul 12;13(1):4032. [Abstract]

    Customer Validation
     PD-L1/PD-1 binding activity assay after treatment with free aPD-L1 (Pembrolizumab) or SPIND2 (40 µg/mL) with or without US irradiation.

  • 1/16

    Pembrolizumab (anti-PD-1) purchased from MedChemExpress. Usage Cited in: Nat Commun. 2022 Jul 12;13(1):4032. [Abstract]

    Customer Validation
     Relative tumor volumes of primary tumors of Panc02 tumor-bearing C57BL/6 mice (n = 6) after systemic injection of saline, free-drug mixture (on day 0, 3, and 6, 4 mg/kg body weight for NLG919 and aPD-L1(Pembrolizumab)), or SPIND2 (0.2 mL, 0.6 mg/mL) with or without US irradiation.

  • 1/16

    Pembrolizumab (anti-PD-1) purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2021 May 9;12(5):465. [Abstract]

    Customer Validation
     4T1 tumor-bearing mice treated with anti-PD-1 mAbs (Pembrolizumab, 10 mg/kg; i.p.; twice a week) or LY2940002 (25 mg/kg; i.p.; twice a week) were euthanized at Day21 and the tumor volume were measured. The results showed that the administration of​ anti-PD-1 mAbs (Pembrolizumab), LY294002, or their combination​ significantly inhibited tumor growth in tumor-bearing mice.

  • 1/16

    Pembrolizumab (anti-PD-1) purchased from MedChemExpress. Usage Cited in: ACS Appl Bio Mater. 2020 Oct 19;3(10):7080-7086. [Abstract]

    Customer Validation
     The immunofluorescence images of the tumor from the PBS- (A), random sequence- (B), anti-PD-1 antibody- (Pembrolizumab (5 mg/kg; s.c.; every other day for 16 days)) (C) and isotype antibody-treated group (D); The scale bar in the images is 50 µm.

  • Pembrolizumab (anti-PD-1) Chemical Structure
    1/16
  • Pembrolizumab (anti-PD-1)
  • Flow cytometry analysis of PD-1 overexpression HEK293 cells labelling PD-1 with Pembrolizumab at 67nM (Red). Goat anti human IgG Fc(Alexa Fluor488) was used as the secondary antibody at 1/400 dilution. Isotype control - human IgG (Blue). Unlabeled control - Unlabelled cells (Gray).